Search

Potential Lenacapavir Supply, 2026-28

Lenacapavir has the potential to reach millions — and the momentum is building. Using the current oral PrEP market as a baseline, this graphic estimates what demand for LEN could look like through 2028 and shows how current donor commitments stack up against that opportunity.

Potential Demand for LEN for PrEP

The top 16 PrEP markets, based on 2024 oral PrEP initiations and the possible 2026 injectable market, assuming 60% of new PrEP users choose an injectable, as seen in implementation studies.

Overview of Key LEN Dose, Volumes, Timelines and Prices

AVAC developed this summary of key information related to LEN to help drive transparency from all stakeholders and, hopefully, to accelerate the speed, scale and equity in its introduction.

Global Health Watch: Proposed US budget cuts, HIV supply chain disruptions, Global Fund commitments, new attempt to weaken US vax policy

Proposed US budget cuts, HIV supply chain disruptions, evolving Global Fund commitments, and a renewed attempt to undermine US vaccine policies highlight a landscape under rapid shifts this week.

Jessica Salzwedel

AVAC and Partners Launch New STI Advocacy Agendas in Kenya, South Africa and Zimbabwe

AVAC and partners are proud to share three new national sexually transmitted infections (STIs) advocacy agendas for Kenya, South Africa and Zimbabwe, providing coordinated agendas to elevate STIs as a national health priority and accelerate actions on R&D and delivery of STI vaccines, diagnostics, prevention and care.

Source of Lenacapavir for PrEP Supply to Early Adopter Countries

The Global Fund, with support from CIFF, and PEPFAR have jointly committed to reaching up to two million people with injectable lenacapavir for PrEP over three years. Supply of LEN began arriving in countries in late 2025 with service delivery planned to start in early 2026.

Global Health Watch: Zambia’s Bilateral MoU, NIH Budget Cut, LEN Pricing & Access, New HIV Prevention Access Framework

This week, the global health world lost a true leader, Stephen Lewis, whose life was defined by an unwavering commitment to creating a better, more just world. Lewis’ unwavering passion and fearless advocacy continue to set the standard, reminding us that global health demands urgency, equity and accountability. This week’s issue follows that charge.

AVAC Mourns the Death of Stephen Lewis

Stephen Lewis was a politician and diplomat who deeply valued the essential role of communities in the HIV response. His was a very rare and impactful role model, and all of us at AVAC are deeply saddened by his passing.

Lenacapavir Implementation Studies

Ongoing and planned implementation studies for the lenacapavir as of March 2026.